Compare Cassava Sciences Inc (FLNA) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Wix.Com Ltd — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Wix.Com Ltd trades at $52.62 (market cap $2.23B). The key difference: Wix.Com Ltd is far larger — about 42× Cassava Sciences Inc's market cap. Which is the better fit depends on your goals.
| FLNA | WIX | |
|---|---|---|
Market Cap | $53.14M | $2.23B |
Sector | Health | Technology |
52-Week High | $4.64 | $184.24 |
52-Week Low | $1.09 | $40.43 |
Enterprise Value | -$33.43M | $1.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Wix.com (WIX) trades at $52.71, up 0.57% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported strong revenue growth to $1.99B in 2025, though net income margin turned negative at -1.97%. Recent news highlights a significant stock decline of 27% in May 2026 following Q1 earnings miss and an unanticipated spike in operating expenses, prompting multiple law firm investigations into potential securities fraud.
The outlook is polarized: strong analyst consensus (67.5% Buy) with an $83.13 price target suggests significant upside, but near-term risks are elevated due to the Q1 earnings miss, ongoing legal investigations, and volatile cash flow trends. Revenue growth remains robust, but profitability challenges and negative shareholder equity create headwinds for sustained value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
